Compare SDGR & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDGR | CMPX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.8M | 927.5M |
| IPO Year | 2020 | 2020 |
| Metric | SDGR | CMPX |
|---|---|---|
| Price | $12.15 | $1.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $21.00 | $14.57 |
| AVG Volume (30 Days) | 1.4M | ★ 12.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | N/A |
| Revenue This Year | $0.76 | N/A |
| Revenue Next Year | $4.60 | $934.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.29 | N/A |
| 52 Week Low | $10.95 | $1.61 |
| 52 Week High | $27.63 | $6.88 |
| Indicator | SDGR | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 26.23 |
| Support Level | $11.18 | $1.61 |
| Resistance Level | $13.36 | $3.54 |
| Average True Range (ATR) | 0.65 | 0.15 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 32.53 | 46.05 |
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.